# Primrose Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/primrose-bio

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.primrosebio.com
- Total disclosed funding: $24M
- Latest round: Series A (Dec 1, 2009)
- Investors on record: 2

## About

Based in California, US, Primrose Bio, Inc. operates as a biotechnology company that focuses on strain engineering and protein production for the development of therapeutics and vaccines for oncology and infectious diseases. Primrose Bio, Inc. was formed in 2023 by the merger of Pelican Technology Holdings (formerly Pfenex Inc.) and Primordial Genetics, Inc. The firm as of September 2026, is led by its CEO, Drew Burch. In September 2026, Primrose Bio, Inc. raised an undisclosed amount of venture funding led by Signet Healthcare Partners, with participation from 1315 Capital, Ligand Pharmaceuticals, Inc., LDV Management, and Agent Capital.

Primrose Bio’s flagship technology, Pfenex Expression Technology®, utilizes Pseudomonas fluorescens for efficient production of complex proteins, including antibodies and vaccine antigens. The Prima RNApols™ platform enhances mRNA production with high yield and quality, while the PeliCRM197® carrier protein is widely used in conjugate vaccines and therapeutics. The company's product portfolio also includes commercialized offerings such as Rylaze®, developed through partnerships and approved by the FDA. 

The company will use the September 2026 funding to expand its technology portfolio and increase the reach of its biologics, mRNA, and vaccine manufacturing technologies.

## Funding rounds

- Series A, Dec 1, 2009, $24M — Dow Venture Capital, Signet Healthcare Partners

## Investors

- Dow Venture Capital (https://capitalatlas.ai/funds/dow-venture-capital) — Series A
- Signet Healthcare Partners (https://capitalatlas.ai/funds/signet-healthcare-partners) — Series A